Drug Profile
SCGB 3A2
Alternative Names: CG1011; Recombinant human secretoglobin 3A2; SCGB3A2Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Clarassance
- Developer Therabron Therapeutics
- Class Recombinant proteins
- Mechanism of Action Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bronchiectasis; Pulmonary fibrosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bronchiectasis in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pulmonary-fibrosis in USA (Parenteral)
- 10 Oct 2013 Preclinical trials in Bronchiectasis in USA (Parenteral)